Skip to main content
Erschienen in: Die Gynäkologie 3/2022

15.02.2022 | Endometriumkarzinom | Gynäkologie aktuell

Neue Aspekte in Diagnostik und Therapie des Endometriumkarzinoms

verfasst von: Prof. Dr. Gerhard Gebauer, Tanja N. Fehm

Erschienen in: Die Gynäkologie | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Auszug

Das Endometriumkarzinom galt viele Jahre als eine Erkrankung älterer Patientinnen, die operativ gut behandelbar ist und sich durch eine relativ gute Prognose auszeichnet. Dies mag erklären, weshalb das Endometriumkarzinom lange Zeit weniger im Focus klinischer Studien zur Optimierung der Therapiestrategien stand. …
Literatur
1.
Zurück zum Zitat Walker JL et al (2009) Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. J Clin Oncol 27:5331–5336 CrossRefPubMedPubMedCentral Walker JL et al (2009) Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. J Clin Oncol 27:5331–5336 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Zullo F, Falbo A, Palomba S (2012) Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 207:94–100 CrossRefPubMed Zullo F, Falbo A, Palomba S (2012) Safety of laparoscopy vs laparotomy in the surgical staging of endometrial cancer: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 207:94–100 CrossRefPubMed
3.
Zurück zum Zitat Ran L et al (2014) Comparison of robotic surgery with laparoscopy and laparotomy for treatment of endometrial cancer: a meta-analysis. PLoS One 9:e108361 CrossRefPubMedPubMedCentral Ran L et al (2014) Comparison of robotic surgery with laparoscopy and laparotomy for treatment of endometrial cancer: a meta-analysis. PLoS One 9:e108361 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18 CrossRefPubMedPubMedCentral Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109:11–18 CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kang S, Yoo HJ, Hwang JH, Lim MC, Seo SS, Park SY (2011) Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 123:522–527 CrossRefPubMed Kang S, Yoo HJ, Hwang JH, Lim MC, Seo SS, Park SY (2011) Sentinel lymph node biopsy in endometrial cancer: meta-analysis of 26 studies. Gynecol Oncol 123:522–527 CrossRefPubMed
6.
Zurück zum Zitat Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, Chi DS et al (2009) Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 115:453–455 CrossRefPubMed Khoury-Collado F, Glaser GE, Zivanovic O, Sonoda Y, Levine DA, Chi DS et al (2009) Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed? Gynecol Oncol 115:453–455 CrossRefPubMed
7.
Zurück zum Zitat Leitao MM, Khoury-Collado F, Gardner G, Sonoda Y, Brown CL, Alektiar KM et al (2013) Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecol Oncol 129:38–41 CrossRefPubMed Leitao MM, Khoury-Collado F, Gardner G, Sonoda Y, Brown CL, Alektiar KM et al (2013) Impact of incorporating an algorithm that utilizes sentinel lymph node mapping during minimally invasive procedures on the detection of stage IIIC endometrial cancer. Gynecol Oncol 129:38–41 CrossRefPubMed
8.
Zurück zum Zitat Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392 CrossRefPubMed Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK et al (2017) A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 18:384–392 CrossRefPubMed
9.
Zurück zum Zitat Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73 CrossRef Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73 CrossRef
10.
Zurück zum Zitat Talhouk A, Hoang LN, McConechy MK et al (2016) Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol 143:46–53 CrossRefPubMedPubMedCentral Talhouk A, Hoang LN, McConechy MK et al (2016) Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: earlier prognostic information to guide treatment. Gynecol Oncol 143:46–53 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ali-Ahmad HM, Rothe M, Mangat PA et al (2021) Pertuzumab plus trastuzumab (P+T) in patients (pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 39(15):5508 CrossRef Ali-Ahmad HM, Rothe M, Mangat PA et al (2021) Pertuzumab plus trastuzumab (P+T) in patients (pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol 39(15):5508 CrossRef
13.
Zurück zum Zitat Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10 CrossRefPubMed Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10 CrossRefPubMed
14.
Zurück zum Zitat Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R (2020) Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 6:1766–1772 CrossRefPubMed Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R (2020) Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 6:1766–1772 CrossRefPubMed
15.
Zurück zum Zitat Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA (2019) Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 20:2786–2794 CrossRef Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA (2019) Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 20:2786–2794 CrossRef
17.
Zurück zum Zitat Dosil MA, Mirantes C, Eritja N, Felip I, Navaridas R, Gatius S, Santacana M, Colàs E, Moiola C, Schoenenberger JA, Encinas M, Garí E, Matias-Guiu X, Dolcet X (2017) Palbociclib has antitumour effects on pten-deficient endometrial neoplasias. J Pathol 242:152–164 CrossRefPubMed Dosil MA, Mirantes C, Eritja N, Felip I, Navaridas R, Gatius S, Santacana M, Colàs E, Moiola C, Schoenenberger JA, Encinas M, Garí E, Matias-Guiu X, Dolcet X (2017) Palbociclib has antitumour effects on pten-deficient endometrial neoplasias. J Pathol 242:152–164 CrossRefPubMed
18.
Zurück zum Zitat Zola P, Ciccone G, Piovano EP et al (2021) Intensive versus minimalist follow-up in patients treated for endometrial cancer: a multicentric randomized controlled trial (the TOTEM study—NCT00916708). J Clin Oncol 39(15):5506 CrossRef Zola P, Ciccone G, Piovano EP et al (2021) Intensive versus minimalist follow-up in patients treated for endometrial cancer: a multicentric randomized controlled trial (the TOTEM study—NCT00916708). J Clin Oncol 39(15):5506 CrossRef
Metadaten
Titel
Neue Aspekte in Diagnostik und Therapie des Endometriumkarzinoms
verfasst von
Prof. Dr. Gerhard Gebauer
Tanja N. Fehm
Publikationsdatum
15.02.2022
Verlag
Springer Medizin
Erschienen in
Die Gynäkologie / Ausgabe 3/2022
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-022-04912-x

Weitere Artikel der Ausgabe 3/2022

Die Gynäkologie 3/2022 Zur Ausgabe

Medizinrecht

Medizinrecht

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.